Market Cap 113.21B
Revenue (ttm) 11.02B
Net Income (ttm) -535.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 28.11
Profit Margin -4.86%
Debt to Equity Ratio 0.00
Volume 2,167,400
Avg Vol 1,709,622
Day's Range N/A - N/A
Shares Out 256.80M
Stochastic %K 17%
Beta 0.41
Analysts Sell
Price Target $514.35

Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 341 6100
Address:
50 Northern Avenue, Boston, United States
Ned_Nosurname
Ned_Nosurname Jun. 22 at 1:27 AM
$CRSP Slightly off-topic, but $VRTX just published this (on an iPSC-derived islet-cell therapy) https://www.nejm.org/doi/full/10.1056/NEJMoa2506549 VRTX paid $100 million upfront ($330 million deal) for non-exclusive rights to CRSP's immune evasion tech for its iPSC-derived islet-cell therapy. CRSP is also working on its own iPSC-derived islet-cell therapy. Along with the core edits for immune evasion (MHC-I KO, PD-L1 KI and HLA-E KI) and cell fitness (TXNIP KO, TNFAIP3 KI and MANF KI) there will be additional ones (undisclosed).
1 · Reply
GoldenTradesCapital
GoldenTradesCapital Jun. 21 at 1:07 PM
Top 5 Biotech Stocks to Keep on Watch 🔬 • $EXAS – Early cancer detection • $CRSP – Gene editing pioneer • $VRTX – Dominates cystic fibrosis • $MRNA – Expanding into RSV and flu • $TMDX – Organ transport tech Follow us for more daily alerts like this one 🔱
0 · Reply
Dimeboy
Dimeboy Jun. 20 at 11:52 PM
$VRTX Kinda like these numbers thx..foot
0 · Reply
footlsfoot
footlsfoot Jun. 20 at 7:27 PM
$VRTX 5740 for journavx retain scripts week ended June 13th. Up from 5372 a week before. Alyftrek was 259 week ended June 13th up from 214 week before (symphony health on Bloomberg intelligence)
1 · Reply
Quantumup
Quantumup Jun. 20 at 4:03 PM
Cantor reiterated $FULC Overweight-$10 and said " $FULC has been a high inbound name that has come up a lot on marketing trips, and a readout that we think the Street is paying close attention to." $PFE $VRTX $CRSP $AGIO NVS ( BLUE - CG) Cantor added, "Generally speaking, many are believers in the mechanism and the potential efficacy profile of inducing fetal hemoglobin (and the nice data that show how increasing rates could reduce vaso-occlusive crises, VOCs). Big questions remaining around the name are 1) what the risk/ benefit profile has to be for doctors to use pociredir and 2) how the FDA will read the data to potentially expand the eligible population. Based on where the stock is trading, we believe there is more value to unlock in the stock, even with the most conservative patient population alone. Should the data exceed expectations, this could potentially open the door to broader market potential, with even more upside to our estimates."
0 · Reply
CelestialIronMan
CelestialIronMan Jun. 20 at 2:46 PM
$SANA we succeeded where $VRTX failed. $2.2B up for grabs in 2021 dollars with a greatly expanded market opportunity due to no immunosuppressive regime required. “RBC predicts that Vertex could have a $2.2 billion market opportunity on its hands for the initial patient population with immunosuppressant therapy. But the real prize will be the non-immunosuppressant population, which Vertex is working to get into human studies. The company said its encapsulated islet cell program is expected to be filed with the FDA for clinical testing in 2022. “ https://www.fiercebiotech.com/biotech/vertex-diabetes-cell-therapy-vx-880-restores-islet-cell-function-single-patient A single patient is producing insulin after treatment with Vertex's new diabetes cell therapy | Fierce Biotech
0 · Reply
CelestialIronMan
CelestialIronMan Jun. 20 at 2:43 PM
$SANA we may get the same consideration as other gene therapies which could potentially shorten the runway, key word could. This is from $VRTX attempt to cure T1D albeit WITH immunosuppression “RBC Capital Markets said the single-patient data shows proof of concept for Vertex's therapy, which could be a "game-changing off-the-shelf approach." Where data on one patient isn't considered significant when testing traditional drugs, it's considered more significant for treatments such as cell and gene therapies.” https://www.fiercebiotech.com/biotech/vertex-diabetes-cell-therapy-vx-880-restores-islet-cell-function-single-patient A single patient is producing insulin after treatment with Vertex's new diabetes cell therapy | Fierce Biotech
0 · Reply
svertical1
svertical1 Jun. 18 at 7:46 PM
$VRTX Not a single Wall Street analyst has Vertex Pain Franchise revenue exceeding (and possibly dwarfing) CF/Casgevy revenue in 3-5 years. Presents timely asymmetrical risk opportunity.
1 · Reply
handmedown1
handmedown1 Jun. 18 at 4:19 PM
$CRSP $VRTX $REGN if either of these comapnies take this out.... crsp mgmt are the worst. Better off to go at it alone.
0 · Reply
svertical1
svertical1 Jun. 18 at 3:33 PM
$VRTX Just opioid replacement is beyond massive! https://www.gminsights.com/industry-analysis/opioid-market Sent from my iPhone
0 · Reply
Latest News on VRTX
Vertex to Participate in Upcoming Investor Conferences

May 15, 2025, 4:05 PM EDT - 5 weeks ago

Vertex to Participate in Upcoming Investor Conferences


Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?

May 6, 2025, 4:28 PM EDT - 6 weeks ago

Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?


Vertex Reports First Quarter 2025 Financial Results

May 5, 2025, 4:01 PM EDT - 6 weeks ago

Vertex Reports First Quarter 2025 Financial Results


GreensKeeper Q1 2025 Portfolio Update

Apr 10, 2025, 8:55 AM EDT - 2 months ago

GreensKeeper Q1 2025 Portfolio Update

AXP CHKP ELV GOOG GOOGL ICE ICLR


Vertex Announces Program Updates for Type 1 Diabetes Portfolio

Mar 28, 2025, 4:05 PM EDT - 3 months ago

Vertex Announces Program Updates for Type 1 Diabetes Portfolio


Final Trades: Vertex Pharma, Netflix and the IYF

Mar 27, 2025, 5:14 PM EDT - 3 months ago

Final Trades: Vertex Pharma, Netflix and the IYF

NFLX IYF


Trade Tracker: Steve Weiss buys Vertex Pharmaceuticals

Mar 24, 2025, 1:19 PM EDT - 3 months ago

Trade Tracker: Steve Weiss buys Vertex Pharmaceuticals


Top 3 Health Care Stocks That May Keep You Up At Night In Q1

Mar 11, 2025, 8:55 AM EDT - 3 months ago

Top 3 Health Care Stocks That May Keep You Up At Night In Q1

SNY TSVT


Vertex to Participate in Upcoming March Investor Conferences

Feb 18, 2025, 4:05 PM EST - 4 months ago

Vertex to Participate in Upcoming March Investor Conferences


Ned_Nosurname
Ned_Nosurname Jun. 22 at 1:27 AM
$CRSP Slightly off-topic, but $VRTX just published this (on an iPSC-derived islet-cell therapy) https://www.nejm.org/doi/full/10.1056/NEJMoa2506549 VRTX paid $100 million upfront ($330 million deal) for non-exclusive rights to CRSP's immune evasion tech for its iPSC-derived islet-cell therapy. CRSP is also working on its own iPSC-derived islet-cell therapy. Along with the core edits for immune evasion (MHC-I KO, PD-L1 KI and HLA-E KI) and cell fitness (TXNIP KO, TNFAIP3 KI and MANF KI) there will be additional ones (undisclosed).
1 · Reply
GoldenTradesCapital
GoldenTradesCapital Jun. 21 at 1:07 PM
Top 5 Biotech Stocks to Keep on Watch 🔬 • $EXAS – Early cancer detection • $CRSP – Gene editing pioneer • $VRTX – Dominates cystic fibrosis • $MRNA – Expanding into RSV and flu • $TMDX – Organ transport tech Follow us for more daily alerts like this one 🔱
0 · Reply
Dimeboy
Dimeboy Jun. 20 at 11:52 PM
$VRTX Kinda like these numbers thx..foot
0 · Reply
footlsfoot
footlsfoot Jun. 20 at 7:27 PM
$VRTX 5740 for journavx retain scripts week ended June 13th. Up from 5372 a week before. Alyftrek was 259 week ended June 13th up from 214 week before (symphony health on Bloomberg intelligence)
1 · Reply
Quantumup
Quantumup Jun. 20 at 4:03 PM
Cantor reiterated $FULC Overweight-$10 and said " $FULC has been a high inbound name that has come up a lot on marketing trips, and a readout that we think the Street is paying close attention to." $PFE $VRTX $CRSP $AGIO NVS ( BLUE - CG) Cantor added, "Generally speaking, many are believers in the mechanism and the potential efficacy profile of inducing fetal hemoglobin (and the nice data that show how increasing rates could reduce vaso-occlusive crises, VOCs). Big questions remaining around the name are 1) what the risk/ benefit profile has to be for doctors to use pociredir and 2) how the FDA will read the data to potentially expand the eligible population. Based on where the stock is trading, we believe there is more value to unlock in the stock, even with the most conservative patient population alone. Should the data exceed expectations, this could potentially open the door to broader market potential, with even more upside to our estimates."
0 · Reply
CelestialIronMan
CelestialIronMan Jun. 20 at 2:46 PM
$SANA we succeeded where $VRTX failed. $2.2B up for grabs in 2021 dollars with a greatly expanded market opportunity due to no immunosuppressive regime required. “RBC predicts that Vertex could have a $2.2 billion market opportunity on its hands for the initial patient population with immunosuppressant therapy. But the real prize will be the non-immunosuppressant population, which Vertex is working to get into human studies. The company said its encapsulated islet cell program is expected to be filed with the FDA for clinical testing in 2022. “ https://www.fiercebiotech.com/biotech/vertex-diabetes-cell-therapy-vx-880-restores-islet-cell-function-single-patient A single patient is producing insulin after treatment with Vertex's new diabetes cell therapy | Fierce Biotech
0 · Reply
CelestialIronMan
CelestialIronMan Jun. 20 at 2:43 PM
$SANA we may get the same consideration as other gene therapies which could potentially shorten the runway, key word could. This is from $VRTX attempt to cure T1D albeit WITH immunosuppression “RBC Capital Markets said the single-patient data shows proof of concept for Vertex's therapy, which could be a "game-changing off-the-shelf approach." Where data on one patient isn't considered significant when testing traditional drugs, it's considered more significant for treatments such as cell and gene therapies.” https://www.fiercebiotech.com/biotech/vertex-diabetes-cell-therapy-vx-880-restores-islet-cell-function-single-patient A single patient is producing insulin after treatment with Vertex's new diabetes cell therapy | Fierce Biotech
0 · Reply
svertical1
svertical1 Jun. 18 at 7:46 PM
$VRTX Not a single Wall Street analyst has Vertex Pain Franchise revenue exceeding (and possibly dwarfing) CF/Casgevy revenue in 3-5 years. Presents timely asymmetrical risk opportunity.
1 · Reply
handmedown1
handmedown1 Jun. 18 at 4:19 PM
$CRSP $VRTX $REGN if either of these comapnies take this out.... crsp mgmt are the worst. Better off to go at it alone.
0 · Reply
svertical1
svertical1 Jun. 18 at 3:33 PM
$VRTX Just opioid replacement is beyond massive! https://www.gminsights.com/industry-analysis/opioid-market Sent from my iPhone
0 · Reply
svertical1
svertical1 Jun. 18 at 2:46 PM
$VRTX The 10 million ‘pain’ patient population mentioned in Barclays call is way underestimated. Worldwide, they’re likely off by a factor >10X+! So yes, very important Vertex rolls out pain drugs methodically given new paradigm being pioneered.
0 · Reply
svertical1
svertical1 Jun. 18 at 5:50 AM
$VRTX Must watch interview! Thanks for posting. 5 P3 Trials! Building solid foundation for Pain franchise as they did with CF. Chronic….DPN & LSR will both be huge! ≈10 Million patients! Growth of VRTX is in early innings!
0 · Reply
FinJay
FinJay Jun. 18 at 3:52 AM
$VRTX https://youtu.be/5aM1K_i_cl4
0 · Reply
JoeB07
JoeB07 Jun. 17 at 2:26 AM
$INSM is now the $PLTR of bio/healthcare. The next $VRTX, but bigger. Like Humira and Keytruda combined. Brenso! Unbelievable potential. Going to ride the upper BBs through the analyst targets and beyond. Have fun. Get rich.!
0 · Reply
GoldenTradesCapital
GoldenTradesCapital Jun. 16 at 6:06 PM
Five biotech stocks catching attention this week 🧬 • $INCY – Breakthrough blood cancer data driving momentum • $VRTX – Gene editing pipeline gaining steam • $TXG – Single-cell innovation in research + diagnostics • $MRNA – New RSV vaccine entering commercialization phase • $CRSP – Riding CRISPR regulatory approvals Follow us for more daily alerts 🔱
0 · Reply
svertical1
svertical1 Jun. 16 at 3:36 PM
$VRTX A bit surprising, I’d think every doc would want to utilize for acute pain. Perhaps there is not an opioid crisis, or is it just an awareness issue.
1 · Reply
NancyPelosi____insider
NancyPelosi____insider Jun. 16 at 1:24 PM
$CRDL keep climbing $RGC $LLY $VRTX
0 · Reply
footlsfoot
footlsfoot Jun. 15 at 4:51 AM
$VRTX journavx retail 5372 Alyftrek 214
1 · Reply
sister
sister Jun. 13 at 8:55 PM
$MRNA in case you missed this: 3:01:26 FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up $NVO $VRTX
0 · Reply
akinyo
akinyo Jun. 12 at 7:56 PM
0 · Reply
svertical1
svertical1 Jun. 12 at 4:38 PM
$VRTX Big gap to fill at $498
0 · Reply
akinyo
akinyo Jun. 11 at 3:03 PM
$VRTX Not excited until $500
1 · Reply